Third-party payer reimbursement disruption
Revenue depends on insurer payment decisions, claim processing, and patient eligibility.
- Scope
- Core device and supply revenue
- Materiality
- high
Zynex Inc
Zynex Inc. is a U.S.-based medical device company headquartered in Englewood, Colorado, focused on electrotherapy and pain management products. Through its operating subsidiaries, it sells and leases devices and supplies used in home and clinical settings, and it also owns a patient-monitoring technology platform developed through its ZMS subsidiary.
4,6 %
79,5 %
1,6 %
+4,4 %
4.46
3.63
| % | |
|---|---|
| Electrotherapy devices | 45% Pain-management and rehabilitation devices sold or leased to patients and providers. |
| Supplies | 45% Recurring consumables used with electrotherapy products, mainly electrodes and batteries. |
| Private-labeled rehabilitation products | 5% Branded support and therapy products sold alongside the core device portfolio. |
| Patient monitoring technologies | 5% Laser-based noninvasive monitoring products under development through ZMS/Kestrel. |
Zynex sells primarily into the U.S. healthcare market, with reimbursement-driven demand from patients using...
- Home-use pain management patientsprimary
Patients who receive electrotherapy devices and recurring supplies for chronic pain or rehabilitation.
- Healthcare payers and insurersprimary
Third-party payers that determine reimbursement levels and claim acceptance for device and supply revenue.
- Physicians and prescribing clinicssecondary
Clinicians that drive patient placement by recommending Zynex devices and related supplies.
- Strategic commercialization partnersemerging
Potential partners for NiCO and HemeOx who could help bring monitoring technologies to market.
Zynex is headquartered in Englewood, Colorado and conducts most of its operations through U.S.-based subsidiaries...
- •Headquartered in Englewood, Colorado
- •Most operations run through U.S. subsidiaries ZMI and ZMS
- •Core revenue is tied to the U.S. healthcare reimbursement system
- •Inactive subsidiaries include Zynex Europe and other legacy entities
- •Trade policy and import exposure can affect sourced components
Zynex’s core strategy centers on selling and supporting electrotherapy devices and recurring supplies through its U.S...
01
Grow core electrotherapy and supply franchiseshort-term
Recurring supplies and device placements are the main commercial engine of the business.
02
Increase sales force productivityshort-term
The company depends on efficient patient acquisition and prescription conversion.
03
Partnerize monitoring technologiesmedium-term
Strategic partners may provide regulatory, commercial, and funding support for NiCO and HemeOx.
Zynex is exposed to reimbursement, payer, and claim-processing risk because a large part of its revenue depends on...
Strategic partnership execution risk
NiCO and HemeOx may require external partners to reach market and generate value.
- Scope
- Monitoring technology pipeline
- Materiality
- high
Tariffs and import cost inflation
Manufactured products and components sourced outside the U.S. may become more expensive.
- Scope
- Cost of revenue and gross margin
- Materiality
- medium
Regulatory and litigation risk
SEC requests and other legal matters can create expense, uncertainty, and reputational damage.
- Scope
- Corporate and operating risk
- Materiality
- medium
Revenue recognition net of payer deductions
Can materially change net revenue and receivables
Allowance for uncollectible accounts
Affects revenue, accounts receivable, and cash conversion
Goodwill and intangible impairment
Can create large non-cash charges
Income tax valuation allowance and discrete items
Affects effective tax rate and net income
: 29.4.2026